Bioterror Researchers Build a More Lethal Mousepox
November 1, 2003
By WILLIAM J. BROAD
Scientists have created a highly lethal virus in an effort
to develop stronger protections against supervirulent forms
of smallpox that terrorists might turn on humans,
researchers said yesterday.
The genetic engineering involved a virus known as mousepox,
which infects mice but is not known to hurt people. Into
that virus the scientists spliced a single gene that made
it superlethal, then tested it on mice treated with
different combinations of a smallpox vaccine and drugs.
The scientists said the results showed that the best
defenses proved quite effective in preventing deadly
disease not only in mice, but probably in humans exposed to
customized smallpox of similar design.
This type of research has been debated for years, with
critics arguing again yesterday that superviruses created
in laboratories could inspire terrorists to create their
own deadly diseases. The mousepox scientists countered that
the research could help deter terrorism by demonstrating
the emergence of more potent medical defenses.
The mousepox research was done at St. Louis University as a
project financed by the National Institute of Allergy and
Infectious Diseases meant to find new protections against
smallpox, which kills one in three victims.
The leaders of the research said that the lethal mouse
virus would have no effect on humans even if it somehow
escaped from the laboratory, which they said was
safeguarded at biosafety level three, the second-highest
degree of security.
"To my knowledge, there's no scientific evidence to suggest
that this kind of research poses any sort of human health
risk," said Mark Buller, a professor of molecular
microbiology at St. Louis University who directed the
mousepox research. Many experiments have shown that
mousepox does not cause disease in humans, he said.
It goes beyond similar research on mousepox that Australian
scientists reported in early 2001. They warned that their
genetic technique, which they said they stumbled onto,
could overpower existing vaccinations and produce deadlier
kinds of biological weapons. The news prompted heated
scientific debate internationally.
Yesterday, Dr. Buller said the St. Louis researchers had
also made a designer form of cowpox, another cousin of
smallpox, to better understand how easy or difficult it
would be to apply the same kind of genetic engineering to
the human smallpox virus and make it more lethal.
Experts said both the threat of such developments and the
federal response seemed part of a theoretical debate, not
something to worry about for now. They split over whether
the research was prudent. Some argued that, given the
accelerating pace of advances in genetic engineering, it
was wise to investigate worst cases and responses.
"If we do not act across a wide range of areas we will be
failing in our responsibilities as global citizens," said
Ken Alibek, a former leader of the Soviet Union's germ
weapons program.
Other experts called such research a slippery slope that
could aid terrorists, and argued that the research should
have had the kind of rigorous peer review that a National
Academy of Sciences panel called for last month in new
recommendations.
"This is bigger than the original Australian work," said
Elisa D. Harris, a Clinton administration arms control
official now at the University of Maryland. "They knew the
mousepox results and deliberately set out to build upon
that work in a way to create a more deadly virus."
"There was a need here," she added, "for consequential
research to be reviewed to weigh the potential risks and
benefits before the work proceeded, and that apparently
didn't happen here."
Dr. Lawrence D. Kerr, a senior official at the White House
Office of Science and Technology Policy, agreed, noting
that the research began before the recommendations were
issued and would have undergone such scrutiny if begun now.
"This is the exactly the kind of scenario" that federal
officials worry about, he said in an interview.
Eradicated two decades ago, smallpox no longer exists in
nature or human populations. Officially, only the United
States and Russia have stocks of the virus, under tight
security. But federal experts suspect that clandestine
supplies of the virus exist or could be fabricated.
The mousepox research was first reported in the current
issue of New Scientist, a British magazine.
It involved inserting into the mousepox virus a mouse gene
that controls interleukin-4, a primary chemical in the
immune system's response to invaders. In the Australian
case, the designer virus so crippled mice's immune system
with extra production of interleukin-4 that the microbe
reproduced wildly, killing mice that had been vaccinated
and leaving others permanently disabled.
Yesterday, Dr. Buller said the St. Louis research made the
killer germ more lethal by inserting the interleukin-4 gene
into an unimportant region of the virus's DNA, unlike the
central part of the genome that the Australians chose. That
allowed the virus to multiply even faster, he said.
"It can't affect humans," he emphasized repeatedly.
The
human smallpox vaccine offered no protection to mice
exposed to the superlethal virus. "They all died," Dr.
Buller said.
The antiviral drug cidofovir similarly failed to give
protection. But a combination of the drug and vaccine, he
added, saved some mice. The researchers found that the best
protection was a combination of cidofovir with a
monoclonial antibody drug that fought the effects of
interleukin-4. "We protected all the mice from a very high
dose" of the virus, he said.
He added that he planned to submit the research for
publication and had no qualms about disclosing the exact
location of the gene transfer. "It's irrelevant" to the
design of a human weapon, he said.
Dr. Buller said that colleagues at the Army's biodefense
institute at Fort Detrick, Md., were planning to test the
superlethal cowpox virus on mice. Yesterday, neither the
White House nor Fort Detrick would comment on whether those
plans had been approved.
The cowpox virus can infect humans, though the resulting
disease is usually mild. Still, critics worry about the
ramifications of such research, for safety and for
precedent. "The issue here," Dr. Harris said, "is the
potential of this research being misapplied for destructive
purposes."